title: Tardive dyskinesia and glucid metabolism.
abstract: A role of insulin-dependent diabetes in the onset of tardive dyskinesia has been reported and relies on weak physiopathological evidence.
  
  
  OBJECTIVE
  To study the relationship between the occurrence of tardive dyskinesia and variations in glucose levels in a population of patients under typical antipsychotic treatment.
  
  
  METHODS
  Sixty-nine patients with a schizophrenic disorder and who had been receiving continuous neuroleptic treatment for at least 2 years were included. Tardive dyskinesias were assessed by the Abnormal Involuntary Movements Scale (AIMS) and glucose levels by glucose oxidase method.
  
  
  RESULTS
  No significant differences in values of fasting glucose (FG) levels, post-prandial glucose (PPG) levels and glycosylated haemoglobin between the groups with and without tardive dyskinesia were found. In the sub-group with normal FG, comparison of post-prandial delta glucose levels (difference between PPG and FG) between the two group with and without tardive dyskinesia showed a significant difference (p < 0.05). This comparison also showed a correlation between post-prandial delta glucose levels and the AIMS score in the group with tardive dyskinesia (r = 0.482, p < 0.05).
  
  
  CONCLUSIONS
  Glucose metabolism could be involved in patients with tardive dyskinesia. Various factors outside antipsychotic treatment can favour a disturbance of glucose metabolism, which may not be severe.
authors.affiliation: CHU Clermont-Ferrand, Service de Psychiatrie B, rue Montalembert, France. gbrousse@chu-clermontferrand.fr
authors.forename: Georges
authors.initials: G
authors.lastname: Brousse
authors.forename: Alexandre
authors.initials: A
authors.lastname: Meary
authors.forename: Jacques
authors.initials: J
authors.lastname: Mouret
authors.forename: Olivier
authors.initials: O
authors.lastname: Blanc
authors.forename: Thierry
authors.initials: T
authors.lastname: Hueber
authors.forename: Philippe
authors.initials: P
authors.lastname: Lemoine
authors.forename: Pierre-Michel
authors.initials: PM
authors.lastname: Llorca
authors.forename: Bernard
authors.initials: B
authors.lastname: Lachaux
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis*; D004409:Dyskinesia, Drug-Induced / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D044882:Glucose Metabolism Disorders / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008297:Male; D019518:Postprandial Period; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose